Document:

valcom_8k-ex1004.htm

     

    EXHIBIT
10.4

     

    EXHIBIT
C

     

    NEITHER
THIS SECURITY NOR THE SECURITIES INTO WHICH THIS SECURITY IS EXERCISABLE HAVE
BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES
COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER
THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY,
MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION
STATEMENT UNDER THE SECURITIES ACT OR PURSUANT TO AN AVAILABLE EXEMPTION FROM,
OR IN A TRANSACTION NOT SUBJECT TO, THE REGISTRATION REQUIREMENTS OF THE
SECURITIES ACT AND IN ACCORDANCE WITH APPLICABLE STATE SECURITIES LAWS AS
EVIDENCED BY A LEGAL OPINION OF COUNSEL TO THE TRANSFEROR TO SUCH EFFECT, THE
SUBSTANCE OF WHICH SHALL BE REASONABLY ACCEPTABLE TO THE
COMPANY.  THIS SECURITY AND THE SECURITIES ISSUABLE UPON EXERCISE OF
THIS SECURITY MAY BE PLEDGED IN CONNECTION WITH A BONA FIDE MARGIN ACCOUNT OR
OTHER LOAN SECURED BY SUCH SECURITIES.

    

    COMMON
STOCK PURCHASE WARRANT

    

    To
Purchase 1,000,000 Shares of Common Stock of

     

    VALCOM,
INC. COMMON STOCK

     

    THIS
COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies
that, for value received, Omnireliant Holdings, Inc.(the “Holder”), is
entitled, upon the terms and subject to the limitations on exercise and the
conditions hereinafter set forth, at any time on or after the date hereof (the
“Initial Exercise
Date”) and on or prior to the close of business on the fifth anniversary
of the Initial Exercise Date (the “Termination Date”)
but not thereafter, to subscribe for and purchase from Valcom, Inc., a Delaware
corporation (the “Company”), up to
1,000,000 shares (the “Warrant Shares”) of
Common Stock, par value $0.001 per share, of the Company (the “Common
Stock”).  The purchase price of one share of Common Stock under
this Warrant shall be equal to the Exercise Price, as defined in Section
2(b).

     

    Section 1.    Definitions.  Capitalized
terms used and not otherwise defined herein shall have the meanings set forth in
that certain Note Purchase Agreement (the “Purchase Agreement”),
dated January 6, 2009, among the Company and the purchasers signatory
thereto.

     

    Section 2.    Exercise.

     

    a)    Exercise of
Warrant.  Exercise of the purchase rights represented by this
Warrant may be made, in whole or in part, at any time or times on or after the
Initial Exercise Date and on or before the Termination Date by delivery to the
Company of a duly executed facsimile copy of the Notice of Exercise Form
annexed  hereto (or such other office or agency of the Company as it
may designate by notice in writing to the registered Holder at the address of
such Holder appearing on the books of the Company); provided, however, within 5
Trading Days of the date said Notice of Exercise is delivered to the Company, if
this Warrant is exercised in full, the Holder shall have surrendered this
Warrant to the Company and the Company shall have received  payment of
the aggregate Exercise Price of the shares thereby purchased by wire transfer or
cashier’s check drawn on a United States bank.  Notwithstanding
anything herein to the contrary, the Holder shall not be required to physically
surrender this Warrant to the Company until the Holder has purchased all of the
Warrant Shares available hereunder and the Warrant has been exercised in
full.  Partial exercises of this Warrant resulting in purchases of a
portion of the total number of Warrant Shares available hereunder shall have the
effect of lowering the outstanding number of Warrant Shares purchasable
hereunder in an amount equal to the applicable number of Warrant Shares
purchased.  The Holder and the Company shall maintain records showing
the number of Warrant Shares purchased and the date of such
purchases.  The Company shall deliver any objection to any Notice of
Exercise Form within 1 Business Day of receipt of such notice.  In the
event of any dispute or discrepancy, the records of the Holder shall be
controlling and determinative in the absence of manifest error. The Holder and
any assignee, by acceptance of this Warrant, acknowledge and agree that, by
reason of the provisions of this paragraph, following the purchase of a portion
of the Warrant Shares hereunder, the number of Warrant Shares available for
purchase hereunder at any given time may be less than the amount stated on the
face hereof.

     

    
      
         

      

      
        1

        
          

        

      

      
         

      

    

     

    b)    Exercise
Price.  The exercise price of the Common Stock under this
Warrant shall be $0.20,
subject to adjustment hereunder (the “Exercise
Price”).

     

    c)    Cashless
Exercise.  If at any time after one year from the date of
issuance of this Warrant there is no effective Registration Statement
registering, or no current prospectus available for, the resale of the Warrant
Shares by the Holder, then this Warrant may also be exercised at such time by
means of a “cashless exercise” in which the Holder shall be entitled to receive
a certificate for the number of Warrant Shares equal to the quotient obtained by
dividing [(A-B) (X)] by (A), where:

     

    
      (A) = the
VWAP on the Trading Day immediately preceding the date of such
election;

    

    

    
      (B) = the
Exercise Price of this Warrant, as adjusted; and

    

    

    
      (X) = the
number of Warrant Shares issuable upon exercise of this Warrant in accordance
with the terms of this Warrant by means of a cash exercise rather than a
cashless exercise.

    

    

    Notwithstanding
anything herein to the contrary, on the Termination Date, this Warrant shall be
automatically exercised via cashless exercise pursuant to this Section
2(c).

    

    d)    Exercise
Limitations.

     

    
      	
              i.  

            	
              Holder’s
      Restrictions.  The Company
      shall not effect any exercise of this Warrant, and a  Holder
      shall not have the right to exercise any portion of this Warrant, pursuant
      to Section 2(c) or otherwise, to the extent that after giving effect to
      such issuance after exercise, such Holder (together with such Holder’s
      affiliates, and any other person or entity acting as a group together with
      such Holder or any of such Holder’s affiliates), as set forth on the
      applicable Notice of Exercise, would beneficially own in excess of 4.99%
      of the number of shares of the Common Stock outstanding immediately after
      giving effect to such issuance.  For purposes of the foregoing
      sentence, the number of shares of Common Stock beneficially owned by such
      Holder and its affiliates shall include the number of shares of Common
      Stock issuable upon exercise of this Warrant with respect to which the
      determination of such sentence is being made, but shall exclude the number
      of shares of Common Stock which would be issuable upon (A) exercise of the
      remaining, nonexercised portion of this Warrant beneficially owned by such
      Holder or any of its affiliates and (B) exercise or conversion of the
      unexercised or nonconverted portion of any other securities of the Company
      (including, without limitation, any other  Preferred Stock or
      Warrants) subject to a limitation on conversion or exercise analogous to
      the limitation contained herein beneficially owned by such Holder or any
      of its affiliates.  Except as set forth in the preceding sentence,
      for purposes of this Section 2(d)(i), beneficial ownership shall be
      calculated in accordance with Section 13(d) of the Exchange Act and the
      rules and regulations promulgated 

            

    

     

    
      
         

      

      
        2

        
          

        

      

      
         

      

    

     

    thereunder, it being acknowledged by a Holder that the Company is
not representing to such Holder that such calculation is in compliance with
Section 13(d) of the Exchange Act and such Holder is solely responsible for any
schedules required to be filed in accordance therewith.   To the
extent that the limitation contained in this Section 2(d) applies, the
determination of whether this Warrant is exercisable (in relation to other
securities owned by such Holder) and of which a portion of this Warrant is
exercisable shall be in the sole discretion of a Holder, and the submission of a
Notice of Exercise shall be deemed to be each Holder’s determination of whether
this Warrant is exercisable (in relation to other securities owned by such
Holder) and of which portion of this Warrant is exercisable, in each case
subject to such aggregate percentage limitation, and the Company shall have no
obligation to verify or confirm the accuracy of such
determination.   In addition, a determination as to any group
status as contemplated above shall be determined in accordance with Section
13(d) of the Exchange Act and the rules and regulations promulgated
thereunder.  For purposes of this Section 2(d), in determining the
number of outstanding shares of Common Stock, a Holder may rely on the number of
outstanding shares of Common Stock as reflected in (x) the Company’s most recent
Form 10-Q or Form 10-K, as the case may be, (y) a more recent public
announcement by the Company or (z) any other notice by the Company or the
Company’s Transfer Agent setting forth the number of shares of Common Stock
outstanding.  Upon the written or oral request of a Holder, the Company
shall within two Trading Days confirm orally and in writing to such Holder the
number of shares of Common Stock then outstanding.  In any case, the number
of outstanding shares of Common Stock shall be determined after giving effect to
the conversion or exercise of securities of the Company, including this Warrant,
by such Holder or its affiliates since the date as of which such number of
outstanding shares of Common Stock was reported.  The provisions of
this Section 2(d) may be waived by such Holder, at the election of such Holder,
upon not less than 61 days’ prior notice to the Company, and the provisions of
this Section 2(d) shall continue to apply until such 61st day (or
such later date, as determined by such Holder, as may be specified in such
notice of waiver). The provisions of this
paragraph shall be implemented in a manner otherwise than in strict conformity
with the terms of this Section 2(d) to correct this paragraph (or any portion
hereof) which may be defective or inconsistent with the intended 4.99%
beneficial ownership limitation herein contained or to make changes or
supplements necessary or desirable to properly give effect to such 4.99%
limitation. The limitations contained in this paragraph shall apply to a
successor holder of this Warrant. The holders of Common Stock of the Company
shall be third party beneficiaries of this Section 2(d) and the Company may not
waive this Section 2(d) without the consent of holders of a majority of its
Common Stock. 

     

    e)    Mechanics of
Exercise.

     

    i.    Authorization of Warrant
Shares.  The Company covenants that all Warrant Shares which
may be issued upon the exercise of the purchase rights represented by this
Warrant will, upon exercise of the purchase rights represented by this Warrant,
be duly authorized, validly issued, fully paid and nonassessable and free from
all taxes, liens and charges in respect of the issue thereof (other than taxes
in respect of any transfer occurring contemporaneously with such
issue).

     

    ii.   Delivery of Certificates
Upon Exercise.  Certificates for shares purchased hereunder
shall be transmitted by the transfer agent of the Company to the Holder by
crediting the account of the Holder’s prime broker with the Depository Trust
Company through its Deposit Withdrawal Agent Commission (“DWAC”) system if the
Company is a participant in such system, and otherwise by physical delivery to
the address specified by the Holder in the Notice of Exercise within 3 Trading
Days from the delivery to the Company of the Notice of Exercise Form, surrender
of this Warrant (if required) and payment of the aggregate Exercise Price as set
forth above (“Warrant
Share Delivery Date”).  This Warrant shall be deemed to have
been exercised on the date the Exercise Price is received by the
Company.  The Warrant Shares shall be deemed to have been issued, and
Holder or any other person so designated to be named therein shall be deemed to
have become a holder of record of such shares for all purposes, as of the date
the Warrant has been exercised by payment to the Company of the Exercise Price
and all taxes required to be paid by the Holder, if any, pursuant to Section
2(e)(vii) prior to the issuance of such shares, have been paid.

     

    iii.   Delivery of New Warrants
Upon Exercise.  If this Warrant shall have been exercised in
part, the Company shall, at the request of a Holder and upon surrender of this
Warrant certificate, at the time of delivery of the certificate or certificates
representing Warrant Shares, deliver to Holder a new Warrant evidencing the
rights of Holder to purchase the unpurchased Warrant Shares called for by this
Warrant, which new Warrant shall in all other respects be identical with this
Warrant.

     

    
      
         

      

      
        3

        
          

        

      

      
         

      

    

     

    iv.   Rescission
Rights.  If the Company fails to cause its transfer agent to
transmit to the Holder a certificate or certificates representing the Warrant
Shares pursuant to this Section 2(e)(iv) by the Warrant Share Delivery Date,
then the Holder will have the right to rescind such exercise.

     

    v.    Compensation for Buy-In on
Failure to Timely Deliver Certificates Upon Exercise.  In
addition to any other rights available to the Holder, if the Company fails to
cause its transfer agent to transmit to the Holder a certificate or certificates
representing the Warrant Shares pursuant to an exercise on or before the Warrant
Share Delivery Date, and if after such date the Holder is required by its broker
to purchase (in an open market transaction or otherwise) shares of Common Stock
to deliver in satisfaction of a sale by the Holder of the Warrant Shares which
the Holder anticipated receiving upon such exercise (a “Buy-In”), then the
Company shall (1) pay in cash to the Holder the amount by which (x) the Holder’s
total purchase price (including brokerage commissions, if any) for the shares of
Common Stock so purchased exceeds (y) the amount obtained by multiplying (A) the
number of Warrant Shares that the Company was required to deliver to the Holder
in connection with the exercise at issue times (B) the price at which the sell
order giving rise to such purchase obligation was executed, and (2) at the
option of the Holder, either reinstate the portion of the Warrant and equivalent
number of Warrant Shares for which such exercise was not honored or deliver to
the Holder the number of shares of Common Stock that would have been issued had
the Company timely complied with its exercise and delivery obligations
hereunder.  For example, if the Holder purchases Common Stock having a
total purchase price of $11,000 to cover a Buy-In with respect to an attempted
exercise of shares of Common Stock with an aggregate sale price giving rise to
such purchase obligation of $10,000, under clause (1) of the immediately
preceding sentence the Company shall be required to pay the Holder $1,000. The
Holder shall provide the Company written notice indicating the amounts payable
to the Holder in respect of the Buy-In, together with applicable confirmations
and other evidence reasonably requested by the Company.  Nothing
herein shall limit a Holder’s right to pursue any other remedies available to it
hereunder, at law or in equity including, without limitation, a decree of
specific performance and/or injunctive relief with respect to the Company’s
failure to timely deliver certificates representing shares of Common Stock upon
exercise of the Warrant as required pursuant to the terms hereof.

     

    vi.   No Fractional Shares or
Scrip.  No fractional shares or scrip representing fractional
shares shall be issued upon the exercise of this Warrant.  As to any
fraction of a share which Holder would otherwise be entitled to purchase upon
such exercise, the Company shall pay a cash adjustment in respect of such final
fraction in an amount equal to such fraction multiplied by the Exercise
Price.

     

    vii.   Charges, Taxes and
Expenses.  Issuance of certificates for Warrant Shares shall be
made without charge to the Holder for any issue or transfer tax or other
incidental expense in respect of the issuance of such certificate, all of which
taxes and expenses shall be paid by the Company, and such certificates shall be
issued in the name of the Holder or in such name or names as may be directed by
the Holder; provided, however, that in the
event certificates for Warrant Shares are to be issued in a name other than the
name of the Holder, this Warrant when surrendered for exercise shall be
accompanied by the Assignment Form attached hereto duly executed by the Holder;
and the Company may require, as a condition thereto, the payment of a sum
sufficient to reimburse it for any transfer tax incidental thereto.

     

    
      
         

      

      
        4

        
          

        

      

      
         

      

       

    

    viii.   Closing of
Books.  The Company will not close its stockholder books or
records in any manner which prevents the timely exercise of this Warrant,
pursuant to the terms hereof.

     

    Section 3.      Certain Adjustments.

     

    a)    Stock Dividends and
Splits. If the Company, at any time while this Warrant is outstanding:
(A) pays a stock dividend or otherwise make a distribution or distributions on
shares of its Common Stock or any other equity or equity equivalent securities
payable in shares of Common Stock (which, for avoidance of doubt, shall not
include any shares of Common Stock issued by the Company pursuant to this
Warrant), (B) subdivides outstanding shares of Common Stock into a larger number
of shares, (C) combines (including by way of reverse stock split) outstanding
shares of Common Stock into a smaller number of shares, or (D) issues by
reclassification of shares of the Common Stock any shares of capital stock of
the Company, then in each case the Exercise Price shall be multiplied by a
fraction of which the numerator shall be the number of shares of Common Stock
(excluding treasury shares, if any) outstanding immediately before such event
and of which the denominator shall be the number of shares of Common Stock
outstanding immediately after such event and the number of shares issuable upon
exercise of this Warrant shall be proportionately adjusted.  Any
adjustment made pursuant to this Section 3(a) shall become effective immediately
after the record date for the determination of stockholders entitled to receive
such dividend or distribution and shall become effective immediately after the
effective date in the case of a subdivision, combination or
re-classification.

     

    b)    Subsequent Equity
Sales. If the Company or any Subsidiary thereof, as applicable, at any
time while this Warrant is outstanding, shall offer, sell, grant any option to
purchase or offer, sell or grant any right to reprice its securities, or
otherwise dispose of or issue (or announce any offer, sale, grant or any option
to purchase or other disposition) any Common Stock or Common Stock Equivalents
entitling any Person to acquire shares of Common Stock, at an effective price
per share less than the then Exercise Price (such lower price, the “Base Share Price” and
such issuances collectively, a “Dilutive Issuance”),
as adjusted hereunder (if the holder of the Common Stock or Common Stock
Equivalents so issued shall at any time, whether by operation of purchase price
adjustments, reset provisions, floating conversion, exercise or exchange prices
or otherwise, or due to warrants, options or rights per share which is issued in
connection with such issuance, be entitled to receive shares of Common Stock at
an effective price per share which is less than the Exercise Price, such
issuance shall be deemed to have occurred for less than the Exercise Price on
such date of the Dilutive Issuance), then the Exercise Price shall be reduced
and only reduced to equal the Base Share Price and the number of Warrant Shares
issuable hereunder shall be increased such that the aggregate Exercise Price
payable hereunder, after taking into account the decrease in the Exercise Price,
shall be equal to the aggregate Exercise Price prior to such
adjustment.  Such adjustment shall be made whenever such Common Stock
or Common Stock Equivalents are issued.  Notwithstanding the
foregoing, no adjustments shall be made, paid or issued under this Section 3(b)
in respect of an Exempt Issuance.  The Company shall notify the Holder
in writing, no later than the Trading Day following the issuance of any Common
Stock or Common Stock Equivalents subject to this section, indicating therein
the applicable issuance price, or of applicable reset price, exchange price,
conversion price and other pricing terms (such notice the “Dilutive Issuance
Notice”).  For purposes of clarification, whether or not the
Company provides a Dilutive Issuance Notice pursuant to this Section 3(b), upon
the occurrence of any Dilutive Issuance, after the date of such Dilutive
Issuance the Holder is entitled to receive a number of Warrant Shares based upon
the Base Share Price regardless of whether the Holder accurately refers to the
Base Share Price in the Notice of Exercise.

     

    c)    Pro Rata
Distributions.  If the Company, at any time prior to the
Termination Date, shall distribute to all holders of Common Stock (and not to
Holders of the Warrants) evidences of its indebtedness or assets (including cash
and cash dividends) or rights or warrants to subscribe for or purchase any
security other than the Common Stock (which shall be subject to Section 3(b)),
then in each such case the Exercise Price shall be adjusted by multiplying the
Exercise Price in effect immediately prior to the record date fixed for
determination of stockholders entitled to receive such distribution by a
fraction of which the denominator shall be the VWAP determined as of the record
date mentioned above, and of which the numerator shall be such VWAP on such
record date less the then per share fair market value at such record date of the
portion of such assets or evidence of indebtedness so distributed applicable to
one outstanding share of the Common Stock as determined by the Board of
Directors in good faith.  In either case the adjustments shall be
described in a statement provided to the Holder of the portion of assets or
evidences of indebtedness so distributed or such subscription rights applicable
to one share of Common Stock.  Such adjustment shall be made whenever
any such distribution is made and shall become effective immediately after the
record date mentioned above.

     

    
      
         

      

      
        5

        
          

        

      

      
         

      

    

     

    d)    Fundamental
Transaction. If, at any time while this Warrant is outstanding, (A) the
Company effects any merger or consolidation of the Company with or into another
Person, (B) the Company effects any sale of all or substantially all of its
assets in one or a series of related transactions, (C) any tender offer or
exchange offer (whether by the Company or another Person) is completed pursuant
to which holders of Common Stock are permitted to tender or exchange their
shares for other securities, cash or property, or (D) the Company effects any
reclassification of the Common Stock or any compulsory share exchange pursuant
to which the Common Stock is effectively converted into or exchanged for other
securities, cash or property (in any such case, a “Fundamental
Transaction”), then, upon any subsequent exercise of this Warrant, the
Holder shall have the right to receive, for each Warrant Share that would have
been issuable upon such exercise immediately prior to the occurrence of such
Fundamental Transaction, at the option of the Holder, (a) upon exercise of this
Warrant, the number of shares of Common Stock of the successor or acquiring
corporation or of the Company, if it is the surviving corporation, and any
additional consideration (the “Alternate
Consideration”) receivable upon or as a result of such reorganization,
reclassification, merger, consolidation or disposition of assets by a Holder of
the number of shares of Common Stock for which this Warrant is exercisable
immediately prior to such event or (b) if the Company is acquired in an all cash
transaction, cash equal to the value of this Warrant as determined in accordance
with the Black-Scholes option pricing formula.  For purposes of any
such exercise, the determination of the Exercise Price shall be appropriately
adjusted to apply to such Alternate Consideration based on the amount of
Alternate Consideration issuable in respect of one share of Common Stock in such
Fundamental Transaction, and the Company shall apportion the Exercise Price
among the Alternate Consideration in a reasonable manner reflecting the relative
value of any different components of the Alternate Consideration.  If
holders of Common Stock are given any choice as to the securities, cash or
property to be received in a Fundamental Transaction, then the Holder shall be
given the same choice as to the Alternate Consideration it receives upon any
exercise of this Warrant following such Fundamental Transaction.  To
the extent necessary to effectuate the foregoing provisions, any successor to
the Company or surviving entity in such Fundamental Transaction shall issue to
the Holder a new warrant consistent with the foregoing provisions and evidencing
the Holder’s right to exercise such warrant into Alternate Consideration. The
terms of any agreement pursuant to which a Fundamental Transaction is effected
shall include terms requiring any such successor or surviving entity to comply
with the provisions of this Section 3(d) and insuring that this Warrant (or any
such replacement security) will be similarly adjusted upon any subsequent
transaction analogous to a Fundamental Transaction.

     

    e)    Calculations. All
calculations under this Section 3 shall be made to the nearest cent or the
nearest 1/100th of a share, as the case may be. For purposes of this Section 3,
the number of shares of Common Stock deemed to be issued and outstanding as of a
given date shall be the sum of the number of shares of Common Stock (excluding
treasury shares, if any) issued and outstanding.

     

    f)    Voluntary Adjustment By
Company. The Company may at any time during the term of this Warrant
reduce the then current Exercise Price to any amount and for any period of time
deemed appropriate by the Board of Directors of the Company.

     

    g)    Notice to
Holders.

     

    i.    Adjustment to Exercise
Price. Whenever the Exercise Price is adjusted pursuant to this Section
3, the Company shall promptly mail to each Holder a notice setting forth the
Exercise Price after such adjustment and setting forth a brief statement of the
facts requiring such adjustment. If the Company issues a variable rate security,
despite the prohibition thereon in the Purchase Agreement, the Company shall be
deemed to have issued Common Stock or Common Stock Equivalents at the lowest
possible conversion or exercise price at which such securities may be converted
or exercised in the case of a Variable Rate Transaction (as defined in the
Purchase Agreement).

     

    
      
         

      

      
        6

        
          

        

      

      
         

      

    

     

    ii.   Notice to Allow Exercise by
Holder. If (A) the Company shall declare a dividend (or any other
distribution) on the Common Stock; (B) the Company shall declare a special
nonrecurring cash dividend on or a redemption of the Common Stock; (C) the
Company shall authorize the granting to all holders of the Common Stock rights
or warrants to subscribe for or purchase any shares of capital stock of any
class or of any rights; (D) the approval of any stockholders of the Company
shall be required in connection with any reclassification of the Common Stock,
any consolidation or merger to which the Company is a party, any sale or
transfer of all or substantially all of the assets of the Company, of any
compulsory share exchange whereby the Common Stock is converted into other
securities, cash or property; (E) the Company shall authorize the voluntary or
involuntary dissolution, liquidation or winding up of the affairs of the
Company; then, in each case, the Company shall cause to be mailed to the Holder
at its last address as it shall appear upon the Warrant Register of the Company,
at least 20 calendar days prior to the applicable record or effective date
hereinafter specified, a notice stating (x) the date on which a record is to be
taken for the purpose of such dividend, distribution, redemption, rights or
warrants, or if a record is not to be taken, the date as of which the holders of
the Common Stock of record to be entitled to such dividend, distributions,
redemption, rights or warrants are to be determined or (y) the date on which
such reclassification, consolidation, merger, sale, transfer or share exchange
is expected to become effective or close, and the date as of which it is
expected that holders of the Common Stock of record shall be entitled to
exchange their shares of the Common Stock for securities, cash or other property
deliverable upon such reclassification, consolidation, merger, sale, transfer or
share exchange; provided that the failure to mail such notice or any defect
therein or in the mailing thereof shall not affect the validity of the corporate
action required to be specified in such notice.  The Holder is
entitled to exercise this Warrant during the 20-day period commencing on the
date of such notice to the effective date of the event triggering such
notice.

     

    Section 4.      
Transfer of
Warrant.

     

    a)    Transferability.  Subject
to compliance with any applicable securities laws and the conditions set forth
in Sections 5(a) and 4(d) hereof and to the provisions of Section 4.1 of the
Purchase Agreement, this Warrant and all rights hereunder are transferable, in
whole or in part, upon surrender of this Warrant at the principal office of the
Company, together with a written assignment of this Warrant substantially in the
form attached hereto duly executed by the Holder or its agent or attorney and
funds sufficient to pay any transfer taxes payable upon the making of such
transfer.  Upon such surrender and, if required, such payment, the
Company shall execute and deliver a new Warrant or Warrants in the name of the
assignee or assignees and in the denomination or denominations specified in such
instrument of assignment, and shall issue to the assignor a new Warrant
evidencing the portion of this Warrant not so assigned, and this Warrant shall
promptly be cancelled.  A Warrant, if properly assigned, may be
exercised by a new holder for the purchase of Warrant Shares without having a
new Warrant issued.

     

    b)    New Warrants. This
Warrant may be divided or combined with other Warrants upon presentation hereof
at the aforesaid office of the Company, together with a written notice
specifying the names and denominations in which new Warrants are to be issued,
signed by the Holder or its agent or attorney.  Subject to compliance
with Section 4(a), as to any transfer which may be involved in such division or
combination, the Company shall execute and deliver a new Warrant or Warrants in
exchange for the Warrant or Warrants to be divided or combined in accordance
with such notice.

     

    c)    Warrant Register. The
Company shall register this Warrant, upon records to be maintained by the
Company for that purpose (the “Warrant Register”),
in the name of the record Holder hereof from time to time.  The
Company may deem and treat the registered Holder of this Warrant as the absolute
owner hereof for the purpose of any exercise hereof or any distribution to the
Holder, and for all other purposes, absent actual notice to the
contrary.

     

    
      
         

      

      
        7

        
          

        

      

      
         

      

    

     

    d)    Transfer
Restrictions. If, at the time of the surrender of this Warrant in connection with
any transfer of this Warrant, the transfer of this Warrant shall not be
registered pursuant to an effective registration statement under the Securities Act and under applicable state securities or blue sky laws, the
Company may require, as a condition of allowing such transfer (i) that the
Holder or transferee of this Warrant, as the case may be, furnish to the Company
a written opinion of counsel (which opinion shall be in form, substance and
scope customary for opinions of counsel in comparable transactions) to the
effect that such transfer may be made without registration under the Securities Act and under applicable state securities
or blue sky laws, (ii) that the holder or transferee execute and deliver to the
Company an investment letter in form and substance acceptable to the Company and
(iii) that the transferee be an “accredited
investor” as defined in Rule 501(a)(1), (a)(2), (a)(3), (a)(7), or (a)(8)
promulgated under the Securities Act or a qualified institutional buyer as
defined in Rule 144A(a) under the Securities Act.

     

    Section 5.      Miscellaneous.

     

    a)    Title to
Warrant.  Prior to the Termination Date and subject to
compliance with applicable laws and Section 4 of this Warrant, this Warrant and
all rights hereunder are transferable, in whole or in part, at the office or
agency of the Company by the Holder in person or by duly authorized attorney,
upon surrender of this Warrant together with the Assignment Form annexed hereto
properly endorsed.  The transferee shall sign an investment letter in
form and substance reasonably satisfactory to the Company.

     

    b)    No Rights as Shareholder
Until Exercise.  This Warrant does not entitle the Holder to
any voting rights or other rights as a shareholder of the Company prior to the
exercise hereof.  Upon the surrender of this Warrant and the payment
of the aggregate Exercise Price (or by means of a cashless exercise), the
Warrant Shares so purchased shall be and be deemed to be issued to such Holder
as the record owner of such shares as of the close of business on the later of
the date of such surrender or payment.

     

    c)    Loss, Theft, Destruction or
Mutilation of Warrant. The Company covenants that upon receipt by the
Company of evidence reasonably satisfactory to it of the loss, theft,
destruction or mutilation of this Warrant or any stock certificate relating to
the Warrant Shares, and in case of loss, theft or destruction, of indemnity or
security reasonably satisfactory to it (which, in the case of the Warrant, shall
not include the posting of any bond), and upon surrender and cancellation of
such Warrant or stock certificate, if mutilated, the Company will make and
deliver a new Warrant or stock certificate of like tenor and dated as of such
cancellation, in lieu of such Warrant or stock certificate.

     

    d)    Saturdays, Sundays,
Holidays, etc.  If the last or appointed day for the taking of
any action or the expiration of any right required or granted herein shall be a
Saturday, Sunday or a legal holiday, then such action may be taken or such right
may be exercised on the next succeeding day not a Saturday, Sunday or legal
holiday.

     

    e)    Authorized
Shares.

     

    The
Company covenants that during the period the Warrant is outstanding, it will
reserve from its authorized and unissued Common Stock a sufficient number of
shares to provide for the issuance of the Warrant Shares upon the exercise of
any purchase rights under this Warrant.  The Company further covenants
that its issuance of this Warrant shall constitute full authority to its
officers who are charged with the duty of executing stock certificates to
execute and issue the necessary certificates for the Warrant Shares upon the
exercise of the purchase rights under this Warrant.  The Company will
take all such reasonable action as may be necessary to assure that such Warrant
Shares may be issued as provided herein without violation of any applicable law
or regulation, or of any requirements of the Trading Market upon which the
Common Stock may be listed.

     

    
      
         

      

      
        8

        
          

        

      

      
         

      

    

     

    Except
and to the extent as waived or consented to by the Holder, the Company shall not
by any action, including, without limitation, amending its certificate of
incorporation or through any reorganization, transfer of assets, consolidation,
merger, dissolution, issue or sale of securities or any other voluntary action,
avoid or seek to avoid the observance or performance of any of the terms of this
Warrant, but will at all times in good faith assist in the carrying out of all
such terms and in the taking of all such actions as may be necessary or
appropriate to protect the rights of Holder as set forth in this Warrant against
impairment.  Without limiting the generality of the foregoing, the
Company will (a) not increase the par value of any Warrant Shares above the
amount payable therefor upon such exercise immediately prior to such increase in
par value, (b) take all such action as may be necessary or appropriate in order
that the Company may validly and legally issue fully paid and nonassessable
Warrant Shares upon the exercise of this Warrant, and (c) use commercially
reasonable efforts to obtain all such authorizations, exemptions or consents
from any public regulatory body having jurisdiction thereof as may be necessary
to enable the Company to perform its obligations under this
Warrant.

     

    Before
taking any action which would result in an adjustment in the number of Warrant
Shares for which this Warrant is exercisable or in the Exercise Price, the
Company shall obtain all such authorizations or exemptions thereof, or consents
thereto, as may be necessary from any public regulatory body or bodies having
jurisdiction thereof.

     

    f)    Jurisdiction. All
questions concerning the construction, validity, enforcement and interpretation
of this Warrant shall be determined in accordance with the provisions of the
Purchase Agreement.

     

    g)    Restrictions.  The
Holder acknowledges that the Warrant Shares acquired upon the exercise of this
Warrant, if not registered, will have restrictions upon resale imposed by state
and federal securities laws.

     

    h)    Nonwaiver and
Expenses.  No course of dealing or any delay or failure to
exercise any right hereunder on the part of Holder shall operate as a waiver of
such right or otherwise prejudice Holder’s rights, powers or remedies,
notwithstanding the fact that all rights hereunder terminate on the Termination
Date.  If the Company willfully and knowingly fails to comply with any
provision of this Warrant, which results in any material damages to the Holder,
the Company shall pay to Holder such amounts as shall be sufficient to cover any
costs and expenses including, but not limited to, reasonable attorneys’ fees,
including those of appellate proceedings, incurred by Holder in collecting any
amounts due pursuant hereto or in otherwise enforcing any of its rights, powers
or remedies hereunder.

     

    i)    Notices.  Any
notice, request or other document required or permitted to be given or delivered
to the Holder by the Company shall be delivered in accordance with the notice
provisions of the Purchase Agreement.

     

    j)    Limitation of
Liability.  No provision hereof, in the absence of any
affirmative action by Holder to exercise this Warrant or purchase Warrant
Shares, and no enumeration herein of the rights or privileges of Holder, shall
give rise to any liability of Holder for the purchase price of any Common Stock
or as a stockholder of the Company, whether such liability is asserted by the
Company or by creditors of the Company.

     

    k)    Remedies.  Holder,
in addition to being entitled to exercise all rights granted by law, including
recovery of damages, will be entitled to specific performance of its rights
under this Warrant.  The Company agrees that monetary damages would
not be adequate compensation for any loss incurred by reason of a breach by it
of the provisions of this Warrant and hereby agrees to waive the defense in any
action for specific performance that a remedy at law would be
adequate.

     

    l)    Successors and
Assigns.  Subject to applicable securities laws, this Warrant
and the rights and obligations evidenced hereby shall inure to the benefit of
and be binding upon the successors of the Company and the successors and
permitted assigns of Holder.  The provisions of this Warrant are
intended to be for the benefit of all Holders from time to time of this Warrant
and shall be enforceable by any such Holder or holder of Warrant
Shares.

     

    
      
         

      

      
        9

        
          

        

      

      
         

      

    

     

    m)    Amendment.  This
Warrant may be modified or amended or the provisions hereof waived with the
written consent of the Company and the Holder.

     

    n)    Severability.  Wherever
possible, each provision of this Warrant shall be interpreted in such manner as
to be effective and valid under applicable law, but if any provision of this
Warrant shall be prohibited by or invalid under applicable law, such provision
shall be ineffective to the extent of such prohibition or invalidity, without
invalidating the remainder of such provisions or the remaining provisions of
this Warrant.

     

    o)    Headings.  The
headings used in this Warrant are for the convenience of reference only and
shall not, for any purpose, be deemed a part of this Warrant.

     

    

    ********************

     

     

    
      
         

      

      
        10

        
          

        

      

      
         

      

    

     

    IN
WITNESS WHEREOF, the Company has caused this Warrant to be executed by its
officer thereunto duly authorized.

     

    Dated:  January
6, 2009

     

    
      
        	 	VALCOM,
      INC.	 
	 	 	 	 
	
                Date

              	
                By:
      

              	/s/ 	 
	 	 	Name:
      Vince Vellardita	 
	 	 	Title:
      Chief Executive Officer	 
	 	 	 	 

      

    

     

     

     

     

    
      
         

      

      
        11

        
          

        

      

      
         

      

    

    

    NOTICE
OF EXERCISE

    

    TO:           _______________________

    

    (1) The
undersigned hereby elects to purchase ________ Warrant Shares of the Company
pursuant to the terms of the attached Warrant (only if exercised in full), and
tenders herewith payment of the exercise price in full, together with all
applicable transfer taxes, if any.

     

    (2) Payment
shall take the form of (check applicable box):

     

    [  ]
in lawful money of the United States; or

     

    [ ] the
cancellation of such number of Warrant Shares as is necessary, in accordance
with the formula set forth in subsection 2(c), to exercise this Warrant with
respect to the maximum number of Warrant Shares purchasable pursuant to the
cashless exercise procedure set forth in subsection 2(c).

     

    (3) Please
issue a certificate or certificates representing said Warrant Shares in the name
of the undersigned or in such other name as is specified below:

     

    _______________________________

    
The
Warrant Shares shall be delivered to the following:

    

    _______________________________

    

    _______________________________

    

    _______________________________

    

    (4)  Accredited
Investor.  The undersigned is an “accredited investor” as
defined in Regulation D promulgated under the Securities Act of 1933, as
amended.

    

    [SIGNATURE
OF HOLDER]

    

    Name of
Investing Entity:
_______________________________________________________________________

    Signature of Authorized Signatory of
Investing Entity:
_________________________________________________

    Name of
Authorized Signatory:
___________________________________________________________________

    Title of
Authorized Signatory:
____________________________________________________________________

    Date:
_______________________________________________________________________________________

    

    
 

    
      
         

      

      
         

        
          

        

      

      
         

      

    

     

    ASSIGNMENT
FORM

    

    (To
assign the foregoing warrant, execute

    this form
and supply required information.

    Do not
use this form to exercise the warrant.)

    
 

    FOR VALUE
RECEIVED, the foregoing Warrant and all rights evidenced thereby are hereby
assigned to

     

    

    _______________________________________________
whose address is

    

    _______________________________________________________________.

    

    

    

    _______________________________________________________________

    

    Dated:  ______________,
_______

    

    

    Holder’s
Signature:             _____________________________

    

    Holder’s
Address:               _____________________________

    

                                                  
_____________________________

    

    

    

    Signature
Guaranteed:  ___________________________________________

    

    

    NOTE:  The
signature to this Assignment Form must correspond with the name as it appears on
the face of the Warrant, without alteration or enlargement or any change
whatsoever, and must be guaranteed by a bank or trust
company.  Officers of corporations and those acting in a fiduciary or
other representative capacity should file proper evidence of authority to assign
the foregoing Warrant.Filed by Bowne Pure Compliance

EXHIBIT 10.1

AGREEMENT

This Agreement, dated as of January 8, 2009 (the “Agreement”), is by and between
Telular Corporation, a Delaware corporation (the “Company”), and Simcoe Partners, L.P.,
Simcoe Management Company, LLC and Jeffrey Jacobowitz (collectively referred to herein as “The
Simcoe Group”).

WHEREAS, the Simcoe Group has filed a preliminary proxy statement on Schedule 14A with the
Securities and Exchange Commission (the “SEC”) for the election of two nominees to the
Board of Directors of the Company at the Company’s 2009 Annual Meeting of Shareholders (including
any adjournment or postponement thereof, the “2009 Annual Meeting”) and conducting a proxy
contest in respect thereof;

WHEREAS, the Company and the Simcoe Group have agreed that it is in their mutual interests and
in the best interests of Company shareholders to enter into this Agreement, which, among other
things, terminates the pending proxy contest for the election of directors at the 2009 Annual
Meeting (the “Proxy Contest”);

WHEREAS, the Company has agreed that, in connection with the 2009 Annual Meeting, the Board
(i) will withdraw the nomination of John E. Berndt for election as a member of the Board and (ii)
will nominate for election as a member of the Board, and recommend that the shareholders vote to
elect as a director of the Company, Jeffrey Jacobowitz, founder of Simcoe Partners, L.P. (the
“Simcoe Nominee”);

WHEREAS, the Simcoe Group has agreed to refrain from submitting any director nominations and
to vote for the election of the Company’s nominees for directors at the 2009 Annual Meeting.

NOW, THEREFORE, in consideration of the mutual covenants and agreements contained herein, and
for other good and valuable consideration, the receipt and sufficiency of which is hereby
acknowledged, the parties hereto agree as follows:

ARTICLE I

DEFINITIONS

Section 1.1 Defined Terms. For purposes of this Agreement:

(a) The term “Affiliate” shall have the meaning set forth in Rule 12b-2 promulgated by
the SEC under the Securities Exchange Act of 1934, as amended (the “Exchange Act”) and
shall include persons who become Affiliates of any party to this Agreement subsequent to the date
hereof.

(b) The term “Board” means the board of directors of the Company.

 

1

 

(c) The term “Common Stock” shall mean the Company’s common stock, par value $.01 per
share.

Section 1.2 Interpretation. When reference is made in this Agreement to a Section,
such reference shall be to a Section of this Agreement unless otherwise indicated. Whenever the
words “include”, “includes” or “including” are used in this Agreement, they shall be deemed to be
followed by the words “without limitation.” The words “hereof,” “herein,” “hereby” and “hereunder”
and words of similar import when used in this Agreement shall refer to this Agreement as a whole
and not to any particular provision of this Agreement. The word “or” shall not be exclusive. This
Agreement shall be construed without regard to any presumption or rule requiring construction or
interpretation against the party drafting or causing any instrument to be drafted.

ARTICLE II

COVENANTS

Section 2.1 Board of Directors, Annual Meeting and Related Matters.

(a) 2009 Annual Meeting. The Company shall use all reasonable best efforts to cause
the 2009 Annual Meeting to be held and the election of directors thereat to be conducted on the
scheduled date of February 3, 2009, and shall not delay or postpone such meeting date or election,
unless a quorum is not obtained, in which case the Company shall hold the meeting as promptly
thereafter as practicable.

(b) Nomination of Directors. The Company agrees that at or in connection with the 2009
Annual Meeting, the Board will:

(1) withdraw and not present the nomination of John E. Berndt as a director of the
Company;

(2) nominate the Simcoe Nominee as a director of the Company for a term expiring at the
2010 annual meeting of shareholders and upon the election and qualification of his
successor; 

(3) recommend that the shareholders of the Company vote to elect the Simcoe Nominee and
the other Company nominees for the Board; and

(4) cause all proxies received by the Company to be voted in the manner specified by
such proxies for election of directors and generally in favor of the Simcoe Nominee and the
other Company nominees where such proxies do not specify how they should be cast.

(c) Efforts. The Company shall use all reasonable best efforts to ensure that the
Simcoe Nominee is elected by the shareholders at the 2009 Annual Meeting.

 

2

 

(d) Role of Simcoe Nominee. The Simcoe Nominee, upon election to the Board, will
serve as an integral member of the Board and will be governed by the same protections and
obligations regarding confidentiality, conflicts of interests, fiduciary duties, trading and
disclosure policies and other governance guidelines and shall have the same rights and benefits,
including with respect to insurance, indemnification, compensation and fees, as are applicable to
all independent directors of the Company.

(e) Proxy Solicitation Materials. The Company and the Board agree that the Company’s
proxy statement and proxy cards for the 2009 Annual Meeting and all other solicitation materials to
be delivered to shareholders in connection with the 2009 Annual Meeting (in each case excepting any
materials delivered prior to the date hereof) shall be prepared in accordance with, and in
furtherance of, this Agreement. The Company will provide the Simcoe Group with copies of any
portion of proxy materials or other solicitation materials that contain statements relating to the
Simcoe Group, the Simcoe Nominee or this Agreement a reasonable period (and, in any event, at least
one business day) in advance of filing such materials with the SEC or disseminating the same in
order to permit the Simcoe Group a reasonable opportunity to review and comment on such materials.
The Simcoe Group will provide, as promptly as reasonably practicable, all information relating to
the Simcoe Nominee (and other information, if any) to the extent required under applicable law to
be included in the Company’s proxy statement and any other solicitation materials to be delivered
to shareholders in connection with the 2009 Annual Meeting.

The Company’s proxy statement for the 2009 Annual Meeting shall contain the same type and
tenor of information concerning the Simcoe Nominee as provided for the Company’s other director
nominees.

(f) Committees. To the extent permitted by law and the Nasdaq listing standards, the
Simcoe Nominee shall be eligible and shall be considered for Committee memberships on the Board to
the same extent as other members of the Board. The Simcoe Nominee shall complete a 2009 Company
Director and Officer Questionnaire to enable the Company to evaluate the Simcoe Nominee’s
independence under applicable independence standards and eligibility to serve on Board committees.

(g) Expenses. Within ten business days of receiving reasonable documentation with
respect to such expenses, the Company shall reimburse the Simcoe Group an amount equal to the
Simcoe Group’s actual out-of-pocket expenses incurred prior to the date of this Agreement in
connection with the Proxy Contest, including the preparation of related filings with the SEC and
the fees and disbursements of counsel and other advisors, up to a maximum reimbursement of $50,000,
and the Simcoe Group hereby agrees that such payment shall be in full satisfaction of any claims or
rights it may have as of the date hereof for reimbursement of fees, expenses or costs in connection
with the Proxy Contest.

Section 2.2 Voting Provisions. The Simcoe Group, together with its Affiliates, will
cause all shares of Common Stock for which they have the right to vote as of the record date for
the 2009 Annual Meeting to be present for quorum purposes and to be voted at such meeting or at any
adjournments or postponements thereof, (x) in favor of each director nominated and recommended by the Board for election at such meeting and (y) against any stockholder
nominations for director which are not approved and recommended by the Board for election at such
meeting.

 

3

 

Section 2.4 Termination of the Proxy Contest; Additional Filings.

(a) The Simcoe Group.

(1) By executing this Agreement, the Simcoe Group hereby irrevocably agrees to
terminate the pending Proxy Contest. Within two business days of the date of this
Agreement, the Simcoe Group shall file with the SEC an amendment to its Schedule 13D with
respect to the Common Stock disclosing the material contents of this Agreement, amending
applicable items to conform to the obligations of the parties hereunder and appending this
Agreement and the Press Release as exhibits thereto.

(2) From the date hereof, the Simcoe Group shall not make, and shall cause its
Affiliates not to make, any objection to the election of any of the Company’s nominees at
the 2009 Annual Meeting or any other statement inconsistent with the provisions of this
Agreement.

(3) The Simcoe Group hereby irrevocably withdraws its December 26, 2008, request to
inspect certain of the Company’s books and records pursuant to Section 220 of the Delaware
General Corporation Law, and shall promptly return to the Company or destroy, in its sole
discretion, all materials and summaries or duplicates thereof that have been delivered to
the Simcoe Group or its representatives pursuant such request prior to the date hereof.

(4) Promptly following the issuance of the press release referred to in Section 2.5,
the Simcoe Group shall notify the SEC that it is withdrawing the preliminary proxy
statement on Schedule 14A it filed with the SEC.

(5) The Simcoe Group agrees not to allege that the Company’s definitive proxy
statement or any additional soliciting materials filed with the SEC in connection with the
2009 Annual Meeting, so long as they conform to the terms of this Agreement (including
Schedule A) and the information furnished by The Simcoe Group to the Company pursuant to
Section 2.1(e), violate any of the rules or regulations promulgated under the Exchange Act,
or contain any untrue statement of a material fact or omit to state a material fact
necessary to make the statement not misleading.

(6) The Simcoe Group agrees not to seek, alone or in concert with others, (a) to call
a meeting of shareholders or solicit consents from shareholders, (b) to obtain
representation on the Board except as otherwise set forth in this Agreement, or (c) to
effect the removal of any member of the Board, in each case prior to the earlier of (i) the
2010 annual meeting of the Company’s shareholders or (ii) March 3, 2010.

 

4

 

(7) The Simcoe Group shall not prior to the 2009 Annual Meeting, sell, assign,
transfer, grant an option with respect to or otherwise dispose of any interest in
(or enter into an agreement or understanding with respect to the foregoing)
(collectively, a “Disposition”) any shares of Common Stock; provided, however, that
the foregoing limitation shall not prohibit any Permitted Disposition. A “Permitted
Disposition” shall mean (i) a Disposition pursuant to a tender offer, an exchange
offer, a merger, sale or any other transaction in which all shareholders of the Company
have a right to participate; or (ii) any Disposition by any member of the Simcoe Group to
any other member of the Simcoe Group. 

(b) The Company.

(1) Within four business days of the execution of this Agreement, the Company shall
file with the SEC a current report on Form 8-K disclosing the material contents of this
Agreement.

(2) From the date hereof, the Company shall not make, and shall cause its Affiliates
not to make, any objection to the election of the Simcoe Nominee at the 2009 Annual Meeting
or any other statement inconsistent with the provisions of this Agreement.

(3) The Company agrees not to allege that the preliminary proxy materials filed by the
Simcoe Group with the SEC in connection with the 2009 Annual Meeting violated any of the
rules or regulations promulgated under the Exchange Act, or contained any untrue statement
of a material fact or omit to state a material fact necessary to make the statement not
misleading.

Section 2.5 Publicity. Promptly after the execution of this Agreement, the Company
and the Simcoe Group will issue a joint press release in the form attached hereto as Schedule
A, it being understood, however, that the Company is solely responsible for the information and
quotations in the release concerning the Company, and the Simcoe Group is responsible for the
information and quotations concerning the Simcoe Group.

ARTICLE III

OTHER PROVISIONS

Section 3.1 Representations and Warranties.

(a) Representations and Warranties of the Company. The Company hereby represents and
warrants that this Agreement and the performance by the Company of its obligations hereunder

(1) has been duly authorized, executed and delivered by it, and is a valid and binding
obligation of the Company, enforceable against the Company in accordance with its terms;

(2) does not require the approval of the shareholders of the Company; and

 

5

 

(3) does not and will not violate any law, any order of any court or other agency of
government, the Certificate of Incorporation of the Company, as amended, or the By-Laws of
the Company, as amended, or any provision of any indenture, agreement or other instrument to
which the Company or any of its properties or assets is bound, or conflict with, result in a
breach of or constitute (with due notice or lapse of time or both) a default under any such
indenture, agreement or other instrument, or result in the creation or imposition of, or
give rise to, any lien, charge, restriction, claim, encumbrance or adverse penalty of any
nature whatsoever pursuant to any such indenture, agreement or other instrument.

(b) Representations and Warranties of the Simcoe Group. The Simcoe Group represents
and warrants that this Agreement and the performance by the Simcoe Group of its obligations
hereunder

(1) has been duly authorized, executed and delivered by the Simcoe Group, and is a
valid and binding obligation of the Simcoe Group, enforceable against the Simcoe Group in
accordance with its terms;

(2) does not require approval by any owners or holders of any equity interest in the
Simcoe Group (except as has already been obtained); and

(3) does not and will not violate any law, any order of any court or other agency of
government, the charter or other organizational documents of the Simcoe Group, as amended,
or any provision of any agreement or other instrument to which the Simcoe Group or any of
its properties or assets is bound, or conflict with, result in a breach of or constitute
(with due notice or lapse of time or both) a default under any such agreement or other
instrument, or result in the creation or imposition of, or give rise to, any lien, charge,
restriction, claim, encumbrance or adverse penalty of any nature whatsoever pursuant to any
such agreement or instrument.

Section 3.2 Release.

(a) By the Simcoe Group. The Simcoe Group hereby agrees for the benefit of the Company, and each
Affiliate, officer, director, shareholder, agent, employee, attorney, assigns, predecessor and
successor, past and present, of the Company (the Company and each such Person being a “Company
Released Person”) as follows: the Simcoe Group, for itself and for its members, officers,
directors, assigns, agents and successors, past and present, hereby agrees and confirms that,
effective from and after the date of this Agreement, it hereby acknowledges full and complete
satisfaction of, and covenant not to sue, and forever fully release and discharge each Company
Released Person of, and hold each Company Released Person harmless from, any and all claims of any
nature whatsoever (“Claims”), whether known or unknown, suspected or unsuspected,
including, but not limited to, those arising in respect of or in connection with the nomination and
election of directors or other actions to be taken at the 2009 Annual Meeting, occurring any time
or period of time on or prior to the date of this Agreement (including the future effects of such
occurrences, conditions, acts or omissions).

 

6

 

(b) By the Company. The Company hereby agrees for the benefit of the Simcoe Group, and each
Affiliate, officer, director, member, partner, manager, shareholder, agent, employee, attorney,
assigns, predecessor and successor, past and present, of each member of the Simcoe Group (the
Simcoe Group and each such Person being a “Simcoe Released Person”) as follows: the
Company, for itself and for its officers, directors, assigns, agents and successors, past and
present, hereby agrees and confirms that, effective from and after the date of this Agreement, it
hereby acknowledges full and complete satisfaction of, and covenants not to sue, and forever fully
releases and discharges each Simcoe Released Person of, and holds each Simcoe Released Person
harmless from, any and all Claims, whether known or unknown, suspected or unsuspected, including,
but not limited to, those arising in respect of or in connection with the nomination and election
of directors or other actions to be taken at the 2009 Annual Meeting, occurring any time or period
of time on or prior to the date of this Agreement (including the future effects of such
occurrences, conditions, acts or omissions).

Section 3.3 Remedies.

(a) Each party hereto hereby acknowledges and agrees, on behalf of itself and its Affiliates,
that irreparable harm would occur in the event any of the provisions of this Agreement were not
performed in accordance with their specific terms or were otherwise breached. It is accordingly
agreed that the parties will be entitled to specific relief hereunder, including an injunction or
injunctions to prevent and enjoin breaches of the provisions of this Agreement and to enforce
specifically the terms and provisions hereof in any state or federal court in New York County in
the State of New York, in addition to any other remedy to which they may be entitled at law or in
equity. Any requirements for the securing or posting of any bond with such remedy are hereby
waived.

(b) Each party hereto agrees, on behalf of itself and its Affiliates, that any actions, suits
or proceedings arising out of or relating to this Agreement or the transactions contemplated hereby
will be brought solely and exclusively in any state or federal court in New York County in the
State of New York (and the parties agree not to commence any action, suit or proceeding relating
thereto except in such courts), and further agrees that service of any process, summons, notice or
document by U.S. registered mail to the respective addresses set forth in Section 3.5 will be
effective service of process for any such action, suit or proceeding brought against any party in
any such court. Each party, on behalf of itself and its Affiliates, irrevocably and unconditionally
waives any objection to the laying of venue of any action, suit or proceeding arising out of this
Agreement or the transactions contemplated hereby, in the state or federal courts in New York
County in the State of New York, and hereby further irrevocably and unconditionally waives and
agrees not to plead or claim in any such court that any such action, suit or proceeding brought in
any such court has been brought in an improper or inconvenient forum.

Section 3.4 Entire Agreement. This Agreement contains the entire understanding of the
parties with respect to the subject matter hereof and may be amended only by an agreement in
writing executed by the parties hereto.

 

7

 

Section 3.5 Notices. All notices, consents, requests, instructions, approvals and
other communications provided for herein and all legal process in regard hereto shall be in writing and shall be deemed validly given, made or served, if (x) given by telecopy, when such
telecopy is transmitted to the telecopy number set forth below and the appropriate confirmation is
received or (y) if given by any other means, when actually received during normal business hours at
the address specified in this subsection:

if to the Company:

Telular Corporation

311 South Wacker Drive, Suite 4300

Chicago, Illinois 60606-6622

Facsimile: (312) 379-8364

Attention: Jonathan Charak

with a copy to:

Covington & Burling LLP

1201 Pennsylvania Avenue, NW

Washington, DC 20004

Facsimile: (202) 778-5258

Attention: Michael C. Cutler, Esq.

if to the Simcoe Group:

Simcoe Partners, L.P.

52 Vanderbilt Avenue

4th Floor

New York, NY 10017

Facsimile: (212) 986-0816

Attention: Jeffrey Jacobowitz

with a copy to:

Kramer Levin Naftalis & Frankel LLP

1177 Avenue of the Americas

New York, NY 10036

Facsimile: (212) 715-8000

Attention: Abbe L. Dienstag, Esq.

Section 3.6 Governing Law. This Agreement shall be governed by and construed and
enforced in accordance with the laws of the State of New York.

Section 3.7 Further Assurances. Each party agrees to take or cause to be taken such
further actions, and to execute, deliver and file or cause to be executed, delivered and filed such
further documents and instruments, and to obtain such consents, as may be reasonably required or
requested by the other party in order to effectuate fully the purposes, terms and conditions of
this Agreement.

 

8

 

Section 3.8 Third-Party Beneficiaries. This Agreement shall inure to the benefit of
and be binding upon the parties hereto and their respective successors and assigns, and nothing in
this Agreement is intended to confer on any person other than the parties hereto or their
respective successors and assigns, any rights, remedies, obligations or liabilities under or by
reason of this Agreement.

Section 3.9 Counterparts. This Agreement may be executed in one or more counterparts,
each of which shall be deemed an original, but all of which together shall constitute one and the
same instrument.

[Signature page follows]

 

9

 

IN WITNESS WHEREOF, each of the parties hereto has executed this Agreement, or caused the same
to be executed by its duly authorized representative as of the date first above written.

	 	 	 	 	 
	 	 	TELULAR CORPORATION
	 
	 	 	 	 
	 

	 	By:
	 	/s/
	 

	 	 	 	 
	 

	 	Name:
	 	Joseph Beatty
	 

	 	Title:
	 	CEO
	 
	 	 	 	 
	 	 	SIMCOE PARTNERS, L.P.

By: Simcoe Management Company, LLC, its general
partner
	 
	 	 	 	 
	 

	 	By:
	 	/s/
	 

	 	 	 	 
	 

	 	Name:
	 	Jeffrey Jacobowitz
	 

	 	Title:
	 	Manager of Simcoe Management Company, LLC

 

10

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00151-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00151-of-00352.parquet"}]]